Приказ основних података о документу
Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery
dc.creator | Petrović, Stanislava | |
dc.creator | Bogavac-Stanojević, Nataša | |
dc.creator | Lakić, Dragana | |
dc.creator | Peco-Antić, Amira | |
dc.creator | Vulicević, Irena | |
dc.creator | Ivanišević, Ivana | |
dc.creator | Kotur-Stevuljević, Jelena | |
dc.creator | Jelić-Ivanović, Zorana | |
dc.date.accessioned | 2019-09-02T11:48:42Z | |
dc.date.available | 2019-09-02T11:48:42Z | |
dc.date.issued | 2015 | |
dc.identifier.issn | 1330-0962 | |
dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/2467 | |
dc.description.abstract | Introduction: Acute kidney injury (AKI) is significant problem in children with congenital heart disease (CHD) who undergo cardiac surgery. The economic impact of a biomarker-based diagnostic strategy for AKI in pediatric populations undergoing CHD surgery is unknown. The aim of this study was to perform the cost effectiveness analysis of using serum cystatin C (sCysC), urine neutrophil gelatinase-associated lipocalin (uNGAL) and urine liver fatty acid-binding protein (uL-FABP) for the diagnosis of AKI in children after cardiac surgery compared with current diagnostic method (monitoring of serum creatinine (sCr) level). Materials and methods: We developed a decision analytical model to estimate incremental cost-effectiveness of different biomarker-based diagnostic strategies compared to current diagnostic strategy. The Markov model was created to compare the lifetime cost associated with using of sCysC, uNGAL, uL-FABP with monitoring of sCr level for the diagnosis of AKI. The utility measurement included in the analysis was quality-adjusted life years (QALY). The results of the analysis are presented as the incremental cost-effectiveness ratio (ICER). Results: Analysed biomarker-based diagnostic strategies for AKI were cost-effective compared to current diagnostic method. However, uNGAL and sCys C strategies yielded higher costs and lower effectiveness compared to uL-FABP strategy. uL-FABP added 1.43 QALY compared to current diagnostic method at an additional cost of $8521.87 per patient. Therefore, ICER for uL-FABP compared to sCr was $5959.35/QALY. Conclusions: Our results suggest that the use of uL-FABP would represent cost effective strategy for early diagnosis of AKI in children after cardiac surgery. | en |
dc.publisher | Croatian Soc Medical Biochemists, Zagreb | |
dc.relation | info:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175035/RS// | |
dc.rights | openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.source | Biochemia Medica | |
dc.subject | acute kidney injury | en |
dc.subject | cardiac surgery | en |
dc.subject | children | en |
dc.subject | biomarkers | en |
dc.subject | cost effectiveness analysis | en |
dc.title | Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery | en |
dc.type | article | |
dc.rights.license | BY-NC-ND | |
dcterms.abstract | Богавац-Станојевић, Наташа; Јелић-Ивановић, Зорана; Лакић, Драгана; Котур-Стевуљевић, Јелена; Иванишевић, Ивана; Вулицевић, Ирена; Пецо-Aнтић, Aмира; Петровић, Станислава; | |
dc.citation.volume | 25 | |
dc.citation.issue | 2 | |
dc.citation.spage | 262 | |
dc.citation.epage | 271 | |
dc.citation.other | 25(2): 262-271 | |
dc.citation.rank | M21 | |
dc.identifier.wos | 000356588100014 | |
dc.identifier.doi | 10.11613/BM.2015.027 | |
dc.identifier.pmid | 26110039 | |
dc.identifier.scopus | 2-s2.0-84930421453 | |
dc.identifier.fulltext | https://farfar.pharmacy.bg.ac.rs//bitstream/id/1145/2465.pdf | |
dc.type.version | publishedVersion |